Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Tandem Diabetes Care Inc Stock Research

TNDM

20.59USD-0.65(-3.06%)Market Closed
Watchlist

Market Summary

USD20.59-0.65
Market Closed
-3.06%

TNDM Alerts

  • 1 major insider buys recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

TNDM Stock Price

TNDM RSI Chart

TNDM Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-5.97

Price/Sales (Trailing)

1.69

EV/EBITDA

-5.79

Price/Free Cashflow

-44.03

TNDM Price/Sales (Trailing)

TNDM Profitability

EBT Margin

-25.17%

Return on Equity

-60.15%

Return on Assets

-21.35%

Free Cashflow Yield

-2.27%

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

790.3M

Revenue Y/Y

-2.17%

Revenue Q/Q

15.67%

TNDM Earnings

Earnings (TTM)

-224.5M

Earnings Y/Y

-137.61%

Earnings Q/Q

71.12%

Price Action

52 Week Range

20.5458.82
(Low)(High)

Last 7 days

-5.3%

Last 30 days

-27.1%

Last 90 days

-17.7%

Trailing 12 Months

-56.5%

TNDM Financial Health

Current Ratio

4.43

TNDM Investor Care

Shares Dilution (1Y)

1.54%

Diluted EPS (TTM)

-3.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TNDM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
Carpenter Rick
sold (taxes)
-3,066
21.75
-141
chief technical officer
2023-09-15
McGroddy-Goetz Kathleen
bought
21,450
21.45
1,000
-
2023-09-15
Carpenter Rick
acquired
-
-
406
chief technical officer
2023-08-28
Sheridan John F
sold (taxes)
-7,685
27.06
-284
president & ceo
2023-08-28
BERGER DAVID B
sold (taxes)
-3,815
27.06
-141
evp & chief operating officer
2023-08-28
Leal James
acquired
-
-
310
chief manufacturing officer
2023-08-28
HANSEN BRIAN B
acquired
-
-
407
evp & chief commercial officer
2023-08-28
HANSEN BRIAN B
sold (taxes)
-3,653
27.06
-135
evp & chief commercial officer
2023-08-28
BERGER DAVID B
acquired
-
-
407
evp & chief operating officer
2023-08-28
Gasser Elizabeth Anne
acquired
-
-
372
evp, chief strategy officer

1–10 of 50

Which funds bought or sold TNDM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
317,246
317,246
-%
2023-09-20
BARCLAYS PLC
reduced
-34.39
-2,472,000
1,622,000
-%
2023-09-12
Farther Finance Advisors, LLC
added
1.00
-7,912
12,393
-%
2023-08-24
Alberta Investment Management Corp
new
-
4,644,170
4,644,170
0.04%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
81.13
40,702
471,168
-%
2023-08-21
BOKF, NA
sold off
-100
-491,015
-
-%
2023-08-21
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
39.96
-95,000
523,000
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.36
-1,338,150
1,925,680
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
13.22
-189,358
410,059
-%
2023-08-18
Legato Capital Management LLC
added
35.55
-79,535
360,149
0.05%

1–10 of 44

Latest Funds Activity

Are funds buying TNDM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TNDM
No. of Funds

Schedule 13G FIlings of Tandem Diabetes Care

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 12, 2023
fmr llc
-
0
SC 13G/A
May 10, 2023
capital world investors
10.0%
6,473,192
SC 13G/A
Apr 10, 2023
vanguard group inc
10.92%
7,047,477
SC 13G/A
Apr 06, 2023
blackrock inc.
14.3%
9,206,880
SC 13G/A
Feb 13, 2023
capital world investors
7.7%
4,978,524
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.53%
6,127,229
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
6,345,760
SC 13G
Jul 11, 2022
fmr llc
-
0
SC 13G/A
Feb 11, 2022
capital world investors
5.6%
3,543,503
SC 13G/A

Recent SEC filings of Tandem Diabetes Care

View All Filings
Date Filed Form Type Document
Sep 19, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 30, 2023
4
Insider Trading
Aug 18, 2023
8-K
Current Report

Peers (Alternatives to Tandem Diabetes Care)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
101.2B
6.7B
-0.75% 50.83%
71.05
15.19
11.75% -0.66%
77.5B
13.4B
6.45% 36.39%
85
5.78
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.3B
5.7B
-8.22% -17.24%
30.48
7.49
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
7.1B
616.6M
-12.54% -24.86%
29.24
11.56
69.52% 343.68%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
1.3B
790.3M
-27.09% -56.49%
-5.97
1.69
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-15.15% 56.11%
-9.32
3.69
44.49% -2.43%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
609.7M
162.9M
-27.67% -61.65%
-11.53
3.74
42.67% 12.82%

Tandem Diabetes Care News

Stockhouse Publishing
2023-09-24 | NDAQ:TNDM | Press Release | Tandem Diabetes Care ....
Stockhouse Publishing,
3 hours ago
GlobeNewswire

Returns for TNDM

Cumulative Returns on TNDM

-18.2%


7-Year Cumulative Returns

-13.9%


5-Year Cumulative Returns

-42.5%


3-Year Cumulative Returns

Risks for TNDM

What is the probability of a big loss on TNDM?

100%


Probability that Tandem Diabetes Care stock will be more than 20% underwater in next one year

81.9%


Probability that Tandem Diabetes Care stock will be more than 30% underwater in next one year.

46.5%


Probability that Tandem Diabetes Care stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TNDM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Tandem Diabetes Care was unfortunately bought at previous high price.

Drawdowns

Financials for Tandem Diabetes Care

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.5%790,349,000794,694,000801,218,000790,712,000765,792,000737,669,000702,799,000660,868,000604,844,000541,941,000498,830,000439,163,000410,217,000394,236,000362,305,000330,106,000281,713,000222,584,000183,866,000147,961,000128,700,000
Gross Profit-0.1%404,590,000404,801,000412,987,000411,193,000403,513,000394,021,000376,215,000353,042,000321,610,000283,546,000260,520,000230,236,000215,606,000211,120,000194,212,000175,475,000146,588,000111,771,00089,822,00065,755,00055,832,000
Operating Expenses4.3%636,485,000610,127,000505,834,000473,525,000410,632,000383,469,000353,562,000324,465,000301,762,000281,167,000268,477,000254,711,000245,076,000230,418,000210,934,000193,781,000174,599,000151,914,000134,453,000120,528,000108,062,000
  S&GA Expenses4.8%369,220,000352,224,000335,681,000309,488,000290,307,000276,216,000261,508,000244,527,000229,832,000213,749,000204,903,000195,947,000190,368,000180,493,000165,735,000152,353,000137,210,000119,273,000105,226,00094,348,00084,967,000
  R&D Expenses-----120,325,000107,253,00092,054,00079,938,00071,930,00067,418,00063,574,00058,765,00054,709,00049,926,00045,199,00041,428,00037,389,00032,641,00029,227,00026,181,00023,096,000
EBITDA100.0%--183,668,000-76,239,000-44,901,000-20,810,00031,914,000---13,112,000-24,375,000-42,328,000-37,293,000-10,320,000-18,904,0006,823,00011,542,000-106,310,000---
EBITDA Margin100.0%--0.23-0.10-0.06-0.030.05---0.02-0.05-0.10-0.09-0.03-0.050.020.04-0.48---
Interest Expenses---4,313,0008,628,000--4,313,0002,874,667--2,707,000----9,928,00012,042,000-10,805,0007,846,0008,778,000
Earnings Before Taxes-10.8%-221,681,000-200,052,000-92,852,000-65,599,000-12,499,0004,601,00015,901,00021,738,0006,569,000-26,731,000-36,282,000-50,640,000-44,100,000-16,412,000-24,604,000-8,682,000-6,048,000--122,560,000--
EBT Margin100.0%--0.25-0.12-0.08-0.020.010.020.030.01-0.05-0.07-0.12-0.11-0.04-0.07------
Net Income-10.2%-224,470,000-203,751,000-94,593,000-67,933,000-13,169,0005,895,00015,566,00021,758,0006,556,000-24,559,000-34,382,000-48,730,000-42,223,000-16,628,000-24,753,000-23,719,000-55,063,000-112,910,000-122,611,000-137,703,000-119,492,000
Net Income Margin100.0%--0.26-0.12-0.09-0.020.010.020.030.01-0.05-0.07-0.11-0.10-0.04-0.07------
Free Cashflow100.0%--21,944,00016,367,00030,063,00050,879,00083,175,00097,179,00094,431,00071,186,00049,819,000-2,739,000-1,186,0009,406,000500,00022,365,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.8%9479541,0531,0481,0371,015905850795754716673616343326293255215206182158
  Current Assets0.8%764758850834835818812755698662637592540281276247213186188163128
    Cash Equivalents2.3%13112817312411594.0071.0011299.0012195.0012922274.0051.0046.0038.0040.0042.0032.0051.00
  Inventory12.2%14813211110588.0080.0069.0066.0067.0067.0064.0071.0062.0060.0049.0041.0027.0023.0020.0024.0025.00
  Net PPE-1.1%74.0075.0069.0073.0059.0050.0050.0050.0049.0050.0050.0049.0044.0038.0033.0028.0023.0017.0017.0018.0018.00
Liabilities0.3%61761561362658757847246144944135034634913613112611094.0075.0066.00132
  Current Liabilities2.0%17517116517413913213212010910310410611410099.0010084.0077.0066.0059.0043.00
Shareholder's Equity-2.8%32933944042245043743339034631336632726820719516714512113111526.00
  Retained Earnings-4.2%-888-853-729-713-664-649-634-645-651-655-659-676-666-639-624-627-624-623-600-603-569
  Additional Paid-In Capital2.3%1,2191,1921,1711,1401,1181,0901,0681,0359979681,0251,003934847820794770744731719595
Accumulated Depreciation---56.00---49.00---39.00---30.00---26.00--
Shares Outstanding0.7%65.0065.0065.0064.0064.0064.0064.0063.0063.0062.0062.0062.0060.0060.0059.0059.0058.0058.0048.0056.0051.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-72.1%5.0018.0050.0064.0074.0096.0011110787.0074.0025.0029.0037.0025.0042.0037.0010.00-0.17-8.32-34.09-49.65
  Share Based Compensation3.7%91.0088.0085.0078.0071.0066.0061.0057.0054.0056.0058.0064.0068.0064.0058.0050.0042.0032.0024.0016.008.00
Cashflow From Investing-40.1%1.002.0033.00-79.43-104-175-186-169-268-335-296-257-141-24.82-56.95-42.64-67.28-80.45-90.74-85.57-39.00
Cashflow From Financing-32.0%9.0013.0017.0027.0046.0052.0052.0045.0056.0030731431228934.0024.0020.0035.0048.00117130112

TNDM Income Statement

2023-06-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Sales$ 195,917$ 200,262$ 365,300$ 376,169
Cost of sales94,18298,316180,658183,130
Gross profit101,735101,946184,642193,039
Operating expenses:    
Selling, general and administrative97,61080,614187,424153,885
Research and development42,93333,57185,09366,731
Acquired in-process research and development expenses0078,7500
Total operating expenses140,543114,185351,267220,616
Operating loss(38,808)(12,239)(166,625)(27,577)
Other income (expense), net:    
Interest income and other, net5,78482611,6491,241
Interest expense(1,605)(1,537)(3,239)(3,053)
Total other income (expense), net4,179(711)8,410(1,812)
Loss before income taxes(34,629)(12,950)(158,215)(29,389)
Income tax expense1,1462,1061,433382
Net loss(35,775)(15,056)(159,648)(29,771)
Other comprehensive income (loss):    
Unrealized gain (loss) on short-term investments(298)(1,124)1,451(3,641)
Foreign currency translation losses(802)(97)(827)(25)
Comprehensive loss$ (36,875)$ (16,277)$ (159,024)$ (33,437)
Net loss per share - basic (in dollars per share)$ (0.55)$ (0.23)$ (2.47)$ (0.47)
Net loss per share - diluted (in dollars per share)$ (0.55)$ (0.24)$ (2.47)$ (0.47)
Weighted average shares used to compute basic net loss per share (in shares)64,83064,07764,69063,979
Weighted average shares used to compute diluted net loss per share (in shares)64,83064,07864,69063,980

TNDM Balance Sheet

2023-06-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 130,751$ 172,517
Short-term investments376,495444,384
Accounts receivable, net98,714114,717
Inventories147,599111,117
Prepaid and other current assets10,7457,241
Total current assets764,304849,976
Property and equipment, net73,75268,552
Operating lease right-of-use assets91,054110,626
Other long-term assets17,56623,631
Total assets946,6761,052,785
Current liabilities:  
Accounts payable57,08055,730
Accrued expenses13,1209,595
Employee-related liabilities35,47338,682
Operating lease liabilities17,75713,121
Deferred revenue23,40118,837
Other current liabilities27,82429,325
Total current liabilities174,655165,290
Convertible senior notes, net - long-term284,128283,232
Operating lease liabilities - long-term118,400123,524
Deferred revenue - long-term15,30516,874
Other long-term liabilities24,95423,918
Total liabilities617,442612,838
Commitments and contingencies (Note 13)00
Stockholders’ equity:  
Common stock, $0.001 par value; 200,000 shares authorized, 65,062 and 64,513 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively.6565
Additional paid-in capital1,219,1991,170,888
Accumulated other comprehensive loss(1,193)(1,817)
Accumulated deficit(888,837)(729,189)
Total stockholders’ equity329,234439,947
Total liabilities and stockholders’ equity$ 946,676$ 1,052,785
John F. Sheridan
2000
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.